Datasets:
Tasks:
Text Classification
Formats:
csv
Sub-tasks:
acceptability-classification
Languages:
English
Size:
100K - 1M
ArXiv:
DOI:
License:
nct_id
stringlengths 11
11
| nlm_download_date_description
null | study_first_submitted_date
stringlengths 10
10
| results_first_submitted_date
stringlengths 10
10
⌀ | disposition_first_submitted_date
nullclasses 493
values | last_update_submitted_date
stringlengths 10
10
| study_first_submitted_qc_date
stringlengths 10
10
| study_first_posted_date
stringlengths 10
10
| study_first_posted_date_type
stringclasses 2
values | results_first_submitted_qc_date
stringlengths 10
10
⌀ | results_first_posted_date
stringlengths 10
10
⌀ | results_first_posted_date_type
stringclasses 2
values | disposition_first_submitted_qc_date
nullclasses 321
values | disposition_first_posted_date
nullclasses 478
values | disposition_first_posted_date_type
nullclasses 2
values | last_update_submitted_qc_date
stringlengths 10
10
| last_update_posted_date
stringlengths 10
10
| last_update_posted_date_type
stringclasses 2
values | start_month_year
stringlengths 7
10
⌀ | start_date_type
stringclasses 2
values | start_date
stringlengths 10
10
⌀ | verification_month_year
stringclasses 151
values | verification_date
stringclasses 151
values | completion_month_year
stringlengths 7
10
| completion_date_type
stringclasses 2
values | completion_date
stringlengths 10
10
| primary_completion_month_year
stringlengths 7
10
| primary_completion_date_type
stringclasses 2
values | primary_completion_date
stringlengths 10
10
| target_duration
null | study_type
stringclasses 1
value | acronym
stringlengths 2
14
⌀ | baseline_population
stringlengths 2
501
⌀ | brief_title
stringlengths 18
300
| official_title
stringlengths 28
563
⌀ | overall_status
stringclasses 4
values | last_known_status
null | phase
stringclasses 7
values | enrollment
float64 0
477k
| enrollment_type
stringclasses 2
values | source
stringlengths 3
107
| limitations_and_caveats
stringlengths 10
503
⌀ | number_of_arms
float64 1
27
⌀ | number_of_groups
null | why_stopped
stringlengths 3
252
⌀ | has_expanded_access
stringclasses 2
values | expanded_access_type_individual
null | expanded_access_type_intermediate
null | expanded_access_type_treatment
null | has_dmc
stringclasses 2
values | is_fda_regulated_drug
stringclasses 2
values | is_fda_regulated_device
stringclasses 2
values | is_unapproved_device
nullclasses 1
value | is_ppsd
null | is_us_export
stringclasses 2
values | biospec_retention
null | biospec_description
null | ipd_time_frame
nullclasses 442
values | ipd_access_criteria
nullclasses 465
values | ipd_url
nullclasses 124
values | plan_to_share_ipd
stringclasses 3
values | plan_to_share_ipd_description
nulllengths 3
998
⌀ | created_at
stringclasses 526
values | updated_at
stringclasses 526
values | source_class
stringclasses 8
values | delayed_posting
null | expanded_access_nctid
nullclasses 80
values | expanded_access_status_for_nctid
nullclasses 4
values | fdaaa801_violation
null | baseline_type_units_analyzed
nullclasses 11
values | patient_registry
null | completion_year
int64 2.02k
2.02k
| labels
float64 0
1
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT01236547 | null | 2010-11-05 | 2021-03-02 | null | 2022-06-28 | 2010-11-05 | 2010-11-07 | ESTIMATED | 2021-04-16 | 2021-05-14 | ACTUAL | null | null | null | 2022-06-28 | 2022-07-19 | ACTUAL | 2010-10-28 | ACTUAL | 2010-10-28 | 2022-05 | 2022-05-31 | 2022-05-20 | ACTUAL | 2022-05-20 | 2020-03-09 | ACTUAL | 2020-03-09 | null | INTERVENTIONAL | null | Eligible participants | Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer | A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer | COMPLETED | null | PHASE2 | 123 | ACTUAL | National Cancer Institute (NCI) | One run-in arm was originally planned; more run-in arms added due to amendments to the protocol regimen unrelated to toxicities. In addition, due to higher than projected rates of ineligibility and consent withdrawals, phase II final analysis was amended to be time-driven (3 years of potential follow-up for all eligible phase II participants) instead of event driven (71 deaths of eligible phase II participants), reducing power from 80% (one-sided alpha 0.15) to 77% (one-sided alpha 0.1379), | 2 | null | null | f | null | null | null | t | null | null | null | null | null | null | null | null | null | null | null | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | NIH | null | null | null | null | null | null | 2,022 | 1 |
NCT03277586 | null | 2017-09-01 | null | null | 2021-01-13 | 2017-09-06 | 2017-09-11 | ACTUAL | null | null | null | null | null | null | 2021-01-13 | 2021-01-15 | ACTUAL | 2018-05-29 | ACTUAL | 2018-05-29 | 2021-01 | 2021-01-31 | 2020-11-30 | ACTUAL | 2020-11-30 | 2020-11-30 | ACTUAL | 2020-11-30 | null | INTERVENTIONAL | EPSD | null | Effects of Probiotics on Symptoms of Depression | Effects of Probiotics on Symptoms of Depression | TERMINATED | null | PHASE3 | 28 | ACTUAL | Queen's University | null | 2 | null | COVID-19 | f | null | null | null | t | f | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT03757715 | null | 2018-11-27 | 2022-03-20 | null | 2022-08-12 | 2018-11-27 | 2018-11-29 | ACTUAL | 2022-08-12 | 2022-08-31 | ACTUAL | null | null | null | 2022-08-12 | 2022-08-31 | ACTUAL | 2019-05-20 | ACTUAL | 2019-05-20 | 2022-08 | 2022-08-31 | 2021-04-12 | ACTUAL | 2021-04-12 | 2021-03-12 | ACTUAL | 2021-03-12 | null | INTERVENTIONAL | null | null | Regional Anesthesia to Reduce Opioid Use Following Functional Endoscopic Sinus Surgery | The Role of Regional Anesthesia to Reduce Opioid Requirements Following Functional Endoscopic Sinus Surgery (FESS) | COMPLETED | null | PHASE4 | 46 | ACTUAL | University of Alabama at Birmingham | null | 2 | null | null | f | null | null | null | null | t | f | null | null | f | null | null | null | null | null | null | null | 2024-10-17 03:57:19.412252 | 2024-10-17 03:57:19.412252 | OTHER | null | null | null | null | null | null | 2,021 | 1 |
NCT05272813 | null | 2022-02-18 | null | null | 2024-07-16 | 2022-02-28 | 2022-03-09 | ACTUAL | null | null | null | null | null | null | 2024-07-16 | 2024-07-18 | ACTUAL | 2022-04-28 | ACTUAL | 2022-04-28 | 2024-07 | 2024-07-31 | 2023-11-28 | ACTUAL | 2023-11-28 | 2023-11-28 | ACTUAL | 2023-11-28 | null | INTERVENTIONAL | null | null | A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL | A Phase I/II Study to Investigate the Efficacy and Safety of MS-553 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | TERMINATED | null | PHASE1/PHASE2 | 13 | ACTUAL | MingSight Pharmaceuticals, Inc | null | 4 | null | The study is terminated due to major protocol revisions. | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | null | null | 2024-10-16 16:13:18.027461 | 2024-10-16 16:13:18.027461 | INDUSTRY | null | null | null | null | null | null | 2,023 | 0 |
NCT05260541 | null | 2022-02-18 | null | null | 2022-11-28 | 2022-02-18 | 2022-03-02 | ACTUAL | null | null | null | null | null | null | 2022-11-28 | 2022-12-01 | ACTUAL | 2022-01-25 | ACTUAL | 2022-01-25 | 2022-11 | 2022-11-30 | 2022-09-23 | ACTUAL | 2022-09-23 | 2022-08-01 | ACTUAL | 2022-08-01 | null | INTERVENTIONAL | null | null | A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder | A Phase 2, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of PRAX-114 in Participants With Post-Traumatic Stress Disorder | TERMINATED | null | PHASE2 | 11 | ACTUAL | Praxis Precision Medicines | null | 3 | null | No longer developing for this indication | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT05556356 | null | 2022-09-22 | null | null | 2024-10-01 | 2022-09-22 | 2022-09-27 | ACTUAL | null | null | null | null | null | null | 2024-10-01 | 2024-10-08 | ACTUAL | 2022-09-13 | ACTUAL | 2022-09-13 | 2024-10 | 2024-10-31 | 2024-05-06 | ACTUAL | 2024-05-06 | 2024-05-06 | ACTUAL | 2024-05-06 | null | INTERVENTIONAL | null | null | Effect of Perioperative Acetaminophen Dosing on Patients Undergoing Surgical Treatment of Basilar Thumb Arthritis | Effect of Perioperative Acetaminophen Dosing on Patients Undergoing Surgical Treatment of Basilar Thumb Arthritis | TERMINATED | null | PHASE4 | 23 | ACTUAL | Indiana Hand to Shoulder Center | null | 2 | null | Physician decision | f | null | null | null | f | t | f | null | null | t | null | null | null | null | null | NO | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | OTHER | null | null | null | null | null | null | 2,024 | 0 |
NCT04888585 | null | 2021-05-13 | 2024-08-19 | null | 2024-09-30 | 2021-05-13 | 2021-05-17 | ACTUAL | 2024-09-30 | 2024-10-08 | ACTUAL | null | null | null | 2024-09-30 | 2024-10-08 | ACTUAL | 2021-06-23 | ACTUAL | 2021-06-23 | 2024-09 | 2024-09-30 | 2023-08-04 | ACTUAL | 2023-08-04 | 2022-08-25 | ACTUAL | 2022-08-25 | null | INTERVENTIONAL | null | The Intent-to-treat (ITT) Population included all participants who were randomized and received at least 1 dose of study drug (N=472). The ITT Population was used for all efficacy analyses.~The Placebo group from Period 1 was re-randomized to either 150 mg or 340 mg for the Long-Term Extension Periods 1 and 2. For the other groups from Period 1 receiving ABBV-154, participants continued receiving ABBV-154 at the same dose and dosing regimen as in Period 1. | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs) | TERMINATED | null | PHASE2 | 473 | ACTUAL | AbbVie | null | 5 | null | Business decision | f | null | null | null | t | t | f | null | null | f | null | null | null | null | null | YES | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,023 | 0 |
NCT03086343 | null | 2017-03-20 | 2020-05-08 | null | 2024-07-17 | 2017-03-20 | 2017-03-22 | ACTUAL | 2020-05-28 | 2020-06-04 | ACTUAL | null | null | null | 2024-07-17 | 2024-07-18 | ACTUAL | 2017-05-09 | ACTUAL | 2017-05-09 | 2024-07 | 2024-07-31 | 2023-06-06 | ACTUAL | 2023-06-06 | 2019-06-13 | ACTUAL | 2019-06-13 | null | INTERVENTIONAL | null | Full Analysis Set: all randomized participants who received at least one dose of study drug during Period 1 | A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs | A Phase 3, Randomized, Active-Controlled, Double-Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) | COMPLETED | null | PHASE3 | 657 | ACTUAL | AbbVie | null | 4 | null | null | f | null | null | null | t | t | f | null | null | f | null | null | null | null | null | YES | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | INDUSTRY | null | null | null | null | null | null | 2,023 | 1 |
NCT04379492 | null | 2020-05-05 | null | null | 2020-10-29 | 2020-05-06 | 2020-05-07 | ACTUAL | null | null | null | null | null | null | 2020-10-29 | 2020-10-30 | ACTUAL | 2020-05-05 | ACTUAL | 2020-05-05 | 2020-10 | 2020-10-31 | 2020-09-25 | ACTUAL | 2020-09-25 | 2020-09-25 | ACTUAL | 2020-09-25 | null | INTERVENTIONAL | null | null | A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19 | Single-center, Phase II, Randomized Double-blind, Placebo-controlled Study of Hydroxychloroquine Compared to Placebo as Treatment for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | Memorial Sloan Kettering Cancer Center | null | 2 | null | Emerging evidence does not support the use of HCQ for treatment or prevention of SARS -CoV2 infection. No pts have been enrolled. | f | null | null | null | null | t | f | null | null | null | null | null | null | null | null | YES | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT04749433 | null | 2021-01-29 | null | null | 2024-10-03 | 2021-02-08 | 2021-02-11 | ACTUAL | null | null | null | null | null | null | 2024-10-03 | 2024-10-08 | ACTUAL | 2021-09-01 | ACTUAL | 2021-09-01 | 2024-10 | 2024-10-31 | 2023-03-30 | ACTUAL | 2023-03-30 | 2023-03-30 | ACTUAL | 2023-03-30 | null | INTERVENTIONAL | null | null | Study of [11C]CPPC to Assess the Safety and Tolerability in Patients With ALS | A Phase 1 Study to Assess the Safety and Tolerability of PET Imaging With [11C]CPPC [5-cyano-N-(4-(4-[11C]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide] Radioligand in Patients With Amyotrophic Lateral Sclerosis | TERMINATED | null | PHASE1 | 4 | ACTUAL | Johns Hopkins University | null | 2 | null | study stopped to enhance protocol and resume under different sponsor | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | OTHER | null | null | null | null | null | null | 2,023 | 0 |
NCT04924413 | null | 2021-05-31 | null | null | 2024-07-02 | 2021-06-09 | 2021-06-14 | ACTUAL | null | null | null | null | null | null | 2024-07-02 | 2024-07-03 | ACTUAL | 2021-07-01 | ACTUAL | 2021-07-01 | 2024-07 | 2024-07-31 | 2024-07-02 | ACTUAL | 2024-07-02 | 2024-07-02 | ACTUAL | 2024-07-02 | null | INTERVENTIONAL | null | null | L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma | L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma | TERMINATED | null | PHASE2 | 9 | ACTUAL | Henan Cancer Hospital | null | 1 | null | Slow enrollment | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | OTHER_GOV | null | null | null | null | null | null | 2,024 | 0 |
NCT00281658 | null | 2006-01-23 | 2011-05-05 | null | 2023-02-09 | 2006-01-24 | 2006-01-25 | ESTIMATED | 2011-05-05 | 2011-06-01 | ESTIMATED | null | null | null | 2023-02-09 | 2023-02-10 | ACTUAL | 2006-01-02 | ACTUAL | 2006-01-02 | 2023-02 | 2023-02-28 | 2021-11-23 | ACTUAL | 2021-11-23 | 2010-06-18 | ACTUAL | 2010-06-18 | null | INTERVENTIONAL | null | null | Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2 | A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study of Lapatinib (GW572016) in Combination With Paclitaxel Versus Paclitaxel Plus Placebo in Subjects With ErbB2 Amplified Metastatic Breast Cancer | COMPLETED | null | PHASE3 | 444 | ACTUAL | Novartis | The data collected for China patients after 01JUL2019 were excluded from analysis due to local regulations in China. | 4 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | YES | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | INDUSTRY | null | null | null | null | null | null | 2,021 | 1 |
NCT04984876 | null | 2021-07-29 | 2024-05-22 | null | 2024-09-13 | 2021-07-29 | 2021-08-02 | ACTUAL | 2024-09-13 | 2024-10-08 | ACTUAL | null | null | null | 2024-09-13 | 2024-10-08 | ACTUAL | 2021-12-07 | ACTUAL | 2021-12-07 | 2024-09 | 2024-09-30 | 2023-11-27 | ACTUAL | 2023-11-27 | 2023-11-27 | ACTUAL | 2023-11-27 | null | INTERVENTIONAL | null | null | Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy | A 52 Week, Multi-center, Randomized, Double-blind Placebo-controlled Study to Assess the Clinical Efficacy and Safety of Ligelizumab (QGE031) in Decreasing the Sensitivity to Peanuts in Patients With Peanut Allergy | TERMINATED | null | PHASE3 | 211 | ACTUAL | Novartis | null | 5 | null | Study terminated by sponsor | null | null | null | null | t | t | f | null | null | null | null | null | null | null | null | YES | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,023 | 0 |
NCT05269121 | null | 2022-02-25 | null | null | 2024-02-21 | 2022-02-25 | 2022-03-07 | ACTUAL | null | null | null | null | null | null | 2024-02-21 | 2024-02-22 | ACTUAL | 2022-09 | ESTIMATED | 2022-09-30 | 2024-02 | 2024-02-29 | 2024-11 | ESTIMATED | 2024-11-30 | 2023-11 | ESTIMATED | 2023-11-30 | null | INTERVENTIONAL | ACTIVE1 | null | Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections | An Open-Label Multicenter Study to Evaluate the Safety and Efficacy of PhageBank™ Phage Therapy in Conjunction With Debridement, Antibiotics, and Implant Retention (DAIR) for Patients With First Time Culture Proven Chronic Prosthetic Joint Infection | WITHDRAWN | null | PHASE1/PHASE2 | 0 | ACTUAL | Adaptive Phage Therapeutics, Inc. | null | 1 | null | Sponsor Decision | null | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | INDUSTRY | null | null | null | null | null | null | 2,024 | 0 |
NCT02767921 | null | 2016-05-06 | null | null | 2021-11-15 | 2016-05-06 | 2016-05-11 | ESTIMATED | null | null | null | null | null | null | 2021-11-15 | 2021-11-24 | ACTUAL | 2016-08-02 | ACTUAL | 2016-08-02 | 2021-11 | 2021-11-30 | 2021-11-15 | ACTUAL | 2021-11-15 | 2020-01-28 | ACTUAL | 2020-01-28 | null | INTERVENTIONAL | null | null | sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer | A Pilot Study of Neoadjuvant sEphB4-HSA in Patients With Genitourinary Cancers | TERMINATED | null | PHASE1 | 2 | ACTUAL | University of Southern California | null | 1 | null | Insufficient accrual | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT03772288 | null | 2018-12-10 | null | null | 2023-02-06 | 2018-12-10 | 2018-12-11 | ACTUAL | null | null | null | null | null | null | 2023-02-06 | 2023-02-08 | ACTUAL | 2019-04-03 | ACTUAL | 2019-04-03 | 2023-02 | 2023-02-28 | 2021-11-17 | ESTIMATED | 2021-11-17 | 2021-11-10 | ESTIMATED | 2021-11-10 | null | INTERVENTIONAL | null | null | A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL) | A Phase 1b Study of TAK-659 in Combination With NKTR-214 in Patients With Advanced Non-Hodgkin Lymphoma | WITHDRAWN | null | PHASE1 | 0 | ACTUAL | Calithera Biosciences, Inc | null | 2 | null | Business Decision: No Safety or Efficacy Concerns | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | YES | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT04886596 | null | 2021-04-29 | 2023-04-10 | null | 2024-09-20 | 2021-05-10 | 2021-05-14 | ACTUAL | 2023-07-14 | 2023-08-04 | ACTUAL | null | null | null | 2024-09-20 | 2024-10-08 | ACTUAL | 2021-05-25 | ACTUAL | 2021-05-25 | 2024-09 | 2024-09-30 | 2024-05-31 | ACTUAL | 2024-05-31 | 2022-04-11 | ACTUAL | 2022-04-11 | null | INTERVENTIONAL | null | null | Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above | A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above | COMPLETED | null | PHASE3 | 26,668 | ACTUAL | GlaxoSmithKline | null | 2 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | YES | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,024 | 1 |
NCT04172844 | null | 2019-11-20 | null | null | 2024-05-31 | 2019-11-20 | 2019-11-21 | ACTUAL | null | null | null | null | null | null | 2024-05-31 | 2024-06-04 | ACTUAL | 2020-01-13 | ACTUAL | 2020-01-13 | 2024-05 | 2024-05-31 | 2022-02-27 | ACTUAL | 2022-02-27 | 2021-12-12 | ACTUAL | 2021-12-12 | null | INTERVENTIONAL | PAVE | null | Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia | A Multisite Phase Ib Study of Pevonedistat, Azacitidine (or Decitabine), and Venetoclax (PAVE) for the Treatment of Patients With Acute Myelogenous Leukemia (AML) | TERMINATED | null | PHASE1 | 16 | ACTUAL | Medical College of Wisconsin | null | 2 | null | Takeda P3001 study didn't meet primary endpoint of improvement in event-free survival. There is no regulatory path forward for pevonedistat. | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT03677401 | null | 2018-09-17 | 2020-10-06 | null | 2021-05-18 | 2018-09-17 | 2018-09-19 | ACTUAL | 2020-10-06 | 2020-10-28 | ACTUAL | null | null | null | 2021-05-18 | 2021-05-20 | ACTUAL | 2018-08-29 | ACTUAL | 2018-08-29 | 2021-05 | 2021-05-31 | 2020-02-06 | ACTUAL | 2020-02-06 | 2020-01-09 | ACTUAL | 2020-01-09 | null | INTERVENTIONAL | null | null | Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis | A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis | COMPLETED | null | PHASE3 | 295 | ACTUAL | Vyne Therapeutics Inc. | null | 2 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | INDUSTRY | null | null | null | null | null | null | 2,020 | 1 |
NCT05457491 | null | 2022-07-11 | 2023-01-05 | null | 2024-09-24 | 2022-07-11 | 2022-07-14 | ACTUAL | 2024-09-24 | 2024-10-04 | ACTUAL | null | null | null | 2024-09-24 | 2024-10-04 | ACTUAL | 2021-10-01 | ACTUAL | 2021-10-01 | 2024-09 | 2024-09-30 | 2022-07-07 | ACTUAL | 2022-07-07 | 2022-07-07 | ACTUAL | 2022-07-07 | null | INTERVENTIONAL | null | null | Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE) | Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE) | TERMINATED | null | PHASE1 | 56 | ACTUAL | Mayo Clinic | Study was terminated early per Principal Investigator | 1 | null | Principal Investigator discretion | f | null | null | null | f | t | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT02451943 | null | 2015-05-20 | 2019-11-27 | null | 2024-09-20 | 2015-05-20 | 2015-05-22 | ESTIMATED | 2019-11-27 | 2019-12-17 | ACTUAL | null | null | null | 2024-09-20 | 2024-10-08 | ACTUAL | 2015-09-14 | ACTUAL | 2015-09-14 | 2024-09 | 2024-09-30 | 2024-06-27 | ACTUAL | 2024-06-27 | 2018-12-05 | ACTUAL | 2018-12-05 | null | INTERVENTIONAL | ANNOUNCE | All randomized participants. | A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma | COMPLETED | null | PHASE3 | 509 | ACTUAL | Eli Lilly and Company | null | 2 | null | null | f | null | null | null | t | null | null | null | null | null | null | null | null | null | null | YES | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,024 | 1 |
NCT04672954 | null | 2020-12-14 | 2023-07-31 | null | 2023-07-31 | 2020-12-14 | 2020-12-17 | ACTUAL | 2023-07-31 | 2024-03-08 | ACTUAL | null | null | null | 2023-07-31 | 2024-03-08 | ACTUAL | 2021-01-07 | ACTUAL | 2021-01-07 | 2023-07 | 2023-07-31 | 2021-07-01 | ACTUAL | 2021-07-01 | 2021-07-01 | ACTUAL | 2021-07-01 | null | INTERVENTIONAL | null | Treated set (TS): all subjects who were entered and treated with one dose of study drug (i.e. verum or placebo). | A Study in Healthy Men to Test How Different Doses of BI 474121 Are Taken up and How They Influence the Amount of a Molecular Messenger (cGMP) in the Spinal Fluid | Pharmacokinetics and Pharmacodynamic Effects of Different Single Oral Doses of BI 474121 in Healthy Male Subjects | COMPLETED | null | PHASE1 | 24 | ACTUAL | Boehringer Ingelheim | null | 5 | null | null | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | INDUSTRY | null | null | null | null | null | null | 2,021 | 1 |
NCT03797872 | null | 2018-12-18 | 2021-02-15 | null | 2021-05-07 | 2019-01-04 | 2019-01-09 | ACTUAL | 2021-05-07 | 2021-05-10 | ACTUAL | null | null | null | 2021-05-07 | 2021-05-10 | ACTUAL | 2019-04-17 | ACTUAL | 2019-04-17 | 2020-03 | 2020-03-31 | 2020-07-16 | ACTUAL | 2020-07-16 | 2020-07-16 | ACTUAL | 2020-07-16 | null | INTERVENTIONAL | POISE | Only one participant was included | Psoriatic Oligoarthritis Intervention With Symptomatic thErapy | Clinical Effectiveness of Symptomatic Therapy Compared to Standard Step up Care for the Treatment of Low Impact Psoriatic Oligoarthritis: a 2 Arm Parallel Group Feasibility Study | COMPLETED | null | PHASE4 | 1 | ACTUAL | University of Oxford | Only 1 participants was eligible and participated in the trial during the recruitment period and this patient was lost to follow up after the baseline visit. | 2 | null | null | f | null | null | null | t | f | f | null | null | f | null | null | null | null | null | UNDECIDED | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT04605614 | null | 2020-10-22 | null | null | 2022-06-07 | 2020-10-22 | 2020-10-28 | ACTUAL | null | null | null | null | null | null | 2022-06-07 | 2022-06-09 | ACTUAL | 2022-08-15 | ESTIMATED | 2022-08-15 | 2022-06 | 2022-06-30 | 2024-10-30 | ESTIMATED | 2024-10-30 | 2024-10-30 | ESTIMATED | 2024-10-30 | null | INTERVENTIONAL | null | null | 64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression | A Phase I Study of 64Cu Pembrolizumab PET Imaging for In Vivo Expression of PD1 | WITHDRAWN | null | PHASE1 | 0 | ACTUAL | City of Hope Medical Center | null | 1 | null | slow accruals | null | null | null | null | null | t | f | null | null | f | null | null | null | null | null | null | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | OTHER | null | null | null | null | null | null | 2,024 | 0 |
NCT02323100 | null | 2014-12-18 | null | null | 2022-03-04 | 2014-12-18 | 2014-12-23 | ESTIMATED | null | null | null | null | null | null | 2022-03-04 | 2022-03-21 | ACTUAL | 2018-12-02 | ACTUAL | 2018-12-02 | 2022-03 | 2022-03-31 | 2022-03-01 | ACTUAL | 2022-03-01 | 2022-03-01 | ACTUAL | 2022-03-01 | null | INTERVENTIONAL | GPBA | null | Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis) | A Double Blind, Placebo Controlled, Dose Escalation Trial of Glycerol Phenylbutyrate Corrector Therapy for Cystic Fibrosis | TERMINATED | null | PHASE1/PHASE2 | 13 | ACTUAL | National Jewish Health | null | 3 | null | funding ended | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | UNDECIDED | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT02589600 | null | 2015-10-27 | 2023-06-16 | null | 2023-09-15 | 2015-10-27 | 2015-10-28 | ESTIMATED | 2023-07-25 | 2023-08-16 | ACTUAL | null | null | null | 2023-09-15 | 2023-09-26 | ACTUAL | 2016-01 | ACTUAL | 2016-01-31 | 2023-09 | 2023-09-30 | 2022-06-22 | ACTUAL | 2022-06-22 | 2022-06-22 | ACTUAL | 2022-06-22 | null | INTERVENTIONAL | ZEST II | Same as participant flow | Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II) | ZEST II for Osteoporotic Fracture Prevention | COMPLETED | null | PHASE4 | 310 | ACTUAL | University of Pittsburgh | null | 2 | null | null | f | null | null | null | t | null | null | null | null | null | null | null | null | null | null | null | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | OTHER | null | null | null | null | null | null | 2,022 | 1 |
NCT03279289 | null | 2017-08-03 | null | null | 2023-04-12 | 2017-09-08 | 2017-09-12 | ACTUAL | null | null | null | null | null | null | 2023-04-12 | 2023-04-13 | ACTUAL | 2017-10-25 | ACTUAL | 2017-10-25 | 2023-04 | 2023-04-30 | 2023-02-09 | ACTUAL | 2023-02-09 | 2023-02-09 | ACTUAL | 2023-02-09 | null | INTERVENTIONAL | AFEMA | null | Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen | Randomised, Multicentre, Phase II Pilot Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With Metastatic Colorectal Cancer (mCRC) After Failure of an Oxaliplatin-based Regimen | COMPLETED | null | PHASE2 | 170 | ACTUAL | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | null | 2 | null | null | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | OTHER | null | null | null | null | null | null | 2,023 | 1 |
NCT02122913 | null | 2014-04-16 | null | null | 2023-11-02 | 2014-04-24 | 2014-04-25 | ESTIMATED | null | null | null | null | null | null | 2023-11-02 | 2023-11-07 | ACTUAL | 2014-05-04 | ACTUAL | 2014-05-04 | 2023-11 | 2023-11-30 | 2021-04-09 | ACTUAL | 2021-04-09 | 2017-02-01 | ACTUAL | 2017-02-01 | null | INTERVENTIONAL | null | null | A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer | A Phase 1 Study of the Oral TRK Inhibitor Larotrectinib in Adult Patients With Solid Tumors | COMPLETED | null | PHASE1 | 75 | ACTUAL | Bayer | null | 7 | null | null | t | null | null | null | f | t | f | null | null | null | null | null | null | null | null | UNDECIDED | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | INDUSTRY | null | null | null | null | null | null | 2,021 | 1 |
NCT03247244 | null | 2017-07-25 | null | null | 2021-01-21 | 2017-08-08 | 2017-08-11 | ACTUAL | null | null | null | null | null | null | 2021-01-21 | 2021-01-25 | ACTUAL | 2018-01-15 | ACTUAL | 2018-01-15 | 2021-01 | 2021-01-31 | 2020-01-27 | ACTUAL | 2020-01-27 | 2019-06-06 | ACTUAL | 2019-06-06 | null | INTERVENTIONAL | null | null | Safety and Efficacy of Cannabis in Tourette Syndrome | A Double-blind, Randomized, Placebo-controlled Crossover Pilot Trial of Medical Cannabis in Adults With Tourette Syndrome | TERMINATED | null | PHASE2 | 15 | ACTUAL | University Health Network, Toronto | null | 4 | null | Recruitment/enrollment took too long | f | null | null | null | f | f | f | null | null | f | null | null | null | null | null | null | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT03602560 | null | 2018-07-18 | 2022-03-23 | null | 2022-07-07 | 2018-07-18 | 2018-07-27 | ACTUAL | 2022-05-04 | 2022-05-31 | ACTUAL | null | null | null | 2022-07-07 | 2022-08-02 | ACTUAL | 2018-10-01 | ACTUAL | 2018-10-01 | 2022-07 | 2022-07-31 | 2020-02-16 | ACTUAL | 2020-02-16 | 2020-02-16 | ACTUAL | 2020-02-16 | null | INTERVENTIONAL | null | null | ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) | A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) | COMPLETED | null | PHASE3 | 265 | ACTUAL | Gilead Sciences | null | 3 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | INDUSTRY | null | null | null | null | null | null | 2,020 | 1 |
NCT02971033 | null | 2016-10-21 | 2022-04-06 | null | 2022-05-10 | 2016-11-18 | 2016-11-22 | ESTIMATED | 2022-05-10 | 2022-06-06 | ACTUAL | null | null | null | 2022-05-10 | 2022-06-06 | ACTUAL | 2018-04-16 | ACTUAL | 2018-04-16 | 2022-05 | 2022-05-31 | 2021-03-31 | ACTUAL | 2021-03-31 | 2021-03-31 | ACTUAL | 2021-03-31 | null | INTERVENTIONAL | null | no patients were randomized to 40mg/day ezetimibe group | Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C | Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C | TERMINATED | null | PHASE2 | 2 | ACTUAL | VA Office of Research and Development | 1. A major limitation is that the study was that it was interrupted by the CoVID-19 pandemic and then was terminated early leading to small numbers of subjects analyzed. It is not possible to derive conclusions comparing the single patients enrolled in arms 1 and 2.~2. The patient in arm 2 had study medication remaining at the first pill count indicating that EZE dosing was lower than 20mg/day during at least part of the treatment period. | 3 | null | Study Funding ended | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | FED | null | null | null | null | null | null | 2,021 | 0 |
NCT03852433 | null | 2019-02-21 | 2024-06-24 | null | 2024-09-24 | 2019-02-21 | 2019-02-25 | ACTUAL | 2024-07-26 | 2024-07-29 | ACTUAL | null | null | null | 2024-09-24 | 2024-10-08 | ACTUAL | 2019-05-31 | ACTUAL | 2019-05-31 | 2024-09 | 2024-09-30 | 2022-09-28 | ACTUAL | 2022-09-28 | 2022-04-05 | ACTUAL | 2022-04-05 | null | INTERVENTIONAL | null | All Randomized Analysis Set included all participants who were enrolled (informed consent signed) and randomized in the study. | Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD) | A Multicenter, Open-label, Randomized Phase 2b Clinical Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Patients With Chronic Hepatitis Delta | COMPLETED | null | PHASE2 | 175 | ACTUAL | Gilead Sciences | null | 4 | null | null | f | null | null | null | f | t | f | null | null | t | null | null | null | null | null | NO | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,022 | 1 |
NCT03005184 | null | 2016-12-22 | null | null | 2018-01-09 | 2016-12-22 | 2016-12-29 | ESTIMATED | null | null | null | null | null | null | 2018-01-09 | 2018-01-11 | ACTUAL | 2017-09 | ESTIMATED | 2017-09-30 | 2018-01 | 2018-01-31 | 2020-01 | ESTIMATED | 2020-01-31 | 2020-01 | ESTIMATED | 2020-01-31 | null | INTERVENTIONAL | null | null | Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2 | Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2 | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | Vanderbilt University Medical Center | null | 12 | null | Study is being redesigned and submitted as a new study. | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT03320876 | null | 2017-10-20 | null | null | 2022-04-20 | 2017-10-20 | 2017-10-25 | ACTUAL | null | null | null | null | null | null | 2022-04-20 | 2022-04-21 | ACTUAL | 2017-07-26 | ACTUAL | 2017-07-26 | 2022-04 | 2022-04-30 | 2021-06-30 | ACTUAL | 2021-06-30 | 2021-06-30 | ACTUAL | 2021-06-30 | null | INTERVENTIONAL | null | null | An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis. | A Multicenter, Open-label, Long-term Extension Safety and Efficacy Study of Filgotinib Treatment in Subjects With Moderately to Severely Active Psoriatic Arthritis. | TERMINATED | null | PHASE2 | 122 | ACTUAL | Galapagos NV | null | 1 | null | development program for filgotinib for participants with psoriatic arthritis has been stopped | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT05567952 | null | 2022-10-03 | 2024-09-17 | null | 2024-09-17 | 2022-10-03 | 2022-10-05 | ACTUAL | 2024-09-17 | 2024-10-08 | ACTUAL | null | null | null | 2024-09-17 | 2024-10-08 | ACTUAL | 2022-10-19 | ACTUAL | 2022-10-19 | 2024-09 | 2024-09-30 | 2024-02-09 | ACTUAL | 2024-02-09 | 2023-09-27 | ACTUAL | 2023-09-27 | null | INTERVENTIONAL | null | Full analysis set (FAS) included all participants randomly assigned to study intervention. | A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir | AN INTERVENTIONAL, EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE A REPEAT 5-DAY COURSE OF NIRMATRELVIR/RITONAVIR COMPARED TO PLACEBO/RITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID-19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY | COMPLETED | null | PHASE2 | 436 | ACTUAL | Pfizer | null | 2 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | YES | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,024 | 1 |
NCT05329623 | null | 2022-03-29 | null | null | 2024-10-03 | 2022-04-07 | 2022-04-15 | ACTUAL | null | null | null | null | null | null | 2024-10-03 | 2024-10-08 | ACTUAL | 2022-05-03 | ACTUAL | 2022-05-03 | 2024-10 | 2024-10-31 | 2024-04-07 | ACTUAL | 2024-04-07 | 2024-04-07 | ACTUAL | 2024-04-07 | null | INTERVENTIONAL | null | null | A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. | A Phase 1, Open-label, Single-dose, Multi-center, Parallel Group Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Matched Healthy Control Participants. | TERMINATED | null | PHASE1 | 33 | ACTUAL | Novartis | null | 4 | null | Sponsor Decision | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,024 | 0 |
NCT02403674 | null | 2015-03-26 | 2018-02-08 | null | 2024-09-30 | 2015-03-26 | 2015-03-31 | ESTIMATED | 2018-03-28 | 2018-04-30 | ACTUAL | null | null | null | 2024-09-30 | 2024-10-08 | ACTUAL | 2015-06-05 | ACTUAL | 2015-06-05 | 2024-09 | 2024-09-30 | 2023-09-07 | ACTUAL | 2023-09-07 | 2017-03-20 | ACTUAL | 2017-03-20 | null | INTERVENTIONAL | DRIVE-AHEAD | The Baseline Analysis Population consists of all randomized participants who received ≥1 dose of study drug. | Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021) | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected Subjects | COMPLETED | null | PHASE3 | 734 | ACTUAL | Merck Sharp & Dohme LLC | null | 2 | null | null | f | null | null | null | t | null | null | null | null | null | null | null | null | null | null | YES | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,023 | 1 |
NCT03822416 | null | 2019-01-28 | 2021-05-03 | null | 2021-05-03 | 2019-01-28 | 2019-01-30 | ACTUAL | 2021-05-03 | 2021-05-25 | ACTUAL | null | null | null | 2021-05-03 | 2021-05-25 | ACTUAL | 2019-03-01 | ACTUAL | 2019-03-01 | 2021-05 | 2021-05-31 | 2020-05-04 | ACTUAL | 2020-05-04 | 2020-05-04 | ACTUAL | 2020-05-04 | null | INTERVENTIONAL | null | null | Treating Smokers With Mental Illness | Treating Tobacco Dependence in Smokers With Severe Mental Illness | COMPLETED | null | PHASE2 | 38 | ACTUAL | University of Minnesota | null | 2 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | OTHER | null | null | null | null | null | null | 2,020 | 1 |
NCT04452006 | null | 2020-06-26 | null | null | 2021-07-06 | 2020-06-26 | 2020-06-30 | ACTUAL | null | null | null | null | null | null | 2021-07-06 | 2021-07-09 | ACTUAL | 2020-07-20 | ACTUAL | 2020-07-20 | 2021-07 | 2021-07-31 | 2021-04-20 | ACTUAL | 2021-04-20 | 2021-04-20 | ACTUAL | 2021-04-20 | null | INTERVENTIONAL | null | null | A Study in Healthy Subjects to Investigate the Safety and Tolerability of ACT- 541478 as Well as What ACT-541478 Does to the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-541478 | Single-center, Double-blind, Randomized, Placebo-controlled, Three-part, First-in-human, Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-541478 in Healthy Subjects | TERMINATED | null | PHASE1 | 56 | ACTUAL | Idorsia Pharmaceuticals Ltd. | null | 11 | null | Based on interim analysis, the Sponsor decided to terminate the study prematurely. | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT04927975 | null | 2021-06-11 | 2024-08-27 | null | 2024-09-30 | 2021-06-11 | 2021-06-16 | ACTUAL | 2024-09-30 | 2024-10-08 | ACTUAL | null | null | null | 2024-09-30 | 2024-10-08 | ACTUAL | 2021-06-30 | ACTUAL | 2021-06-30 | 2024-09 | 2024-09-30 | 2023-08-29 | ACTUAL | 2023-08-29 | 2023-01-13 | ACTUAL | 2023-01-13 | null | INTERVENTIONAL | null | ITT Population in Period 1 (ITT_1): all randomized participants in Period 1, analyzed according to the treatment groups that they were randomized to. | Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Non-Segmental Vitiligo | COMPLETED | null | PHASE2 | 185 | ACTUAL | AbbVie | null | 5 | null | null | f | null | null | null | t | t | f | null | null | t | null | null | null | null | null | YES | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,023 | 1 |
NCT02335944 | null | 2014-10-09 | 2023-01-10 | null | 2023-05-24 | 2015-01-07 | 2015-01-12 | ESTIMATED | 2023-05-24 | 2023-06-18 | ACTUAL | null | null | null | 2023-05-24 | 2023-06-18 | ACTUAL | 2015-01-13 | ACTUAL | 2015-01-13 | 2023-05 | 2023-05-31 | 2020-11-10 | ACTUAL | 2020-11-10 | 2020-11-10 | ACTUAL | 2020-11-10 | null | INTERVENTIONAL | null | No participants were enrolled in Phase II-Group 5 arm due to early study termination. | Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. | A Phase Ib/II, Multicenter, Open-label Study of EGF816 in Combination With INC280 in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer. | TERMINATED | null | PHASE1/PHASE2 | 177 | ACTUAL | Novartis | null | 6 | null | Company decision | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | YES | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT06102174 | null | 2023-10-06 | null | null | 2024-10-03 | 2023-10-20 | 2023-10-26 | ACTUAL | null | null | null | null | null | null | 2024-10-03 | 2024-10-08 | ACTUAL | 2024-02-15 | ACTUAL | 2024-02-15 | 2024-10 | 2024-10-31 | 2024-09-03 | ACTUAL | 2024-09-03 | 2024-09-03 | ACTUAL | 2024-09-03 | null | INTERVENTIONAL | null | null | A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV | AN INTERVENTIONAL, PHASE 1b, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, MULTI-CENTER, DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SISUNATOVIR IN PEDIATRIC PARTICIPANTS UP TO AGE 60 MONTHS WITH RESPIRATORY SYNCYTIAL VIRUS (RSV) LOWER RESPIRATORY TRACT INFECTION (LRTI) | TERMINATED | null | PHASE1 | 10 | ACTUAL | Pfizer | null | 2 | null | Study discontinued due to business reasons. There were no safety concerns in the decision to stop study and no changes to sponsor's assessment of the risk-benefit profile for participants who received sisunatovir in the study | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,024 | 0 |
NCT03361345 | null | 2017-11-17 | null | null | 2023-05-12 | 2017-12-01 | 2017-12-04 | ACTUAL | null | null | null | null | null | null | 2023-05-12 | 2023-05-16 | ACTUAL | 2018-11-01 | ACTUAL | 2018-11-01 | 2023-05 | 2023-05-31 | 2022-01-09 | ACTUAL | 2022-01-09 | 2022-01-09 | ACTUAL | 2022-01-09 | null | INTERVENTIONAL | null | null | Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris | Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris | WITHDRAWN | null | PHASE2/PHASE3 | 0 | ACTUAL | Wayne State University | null | 2 | null | Lack of recruitment | f | null | null | null | t | t | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT04816526 | null | 2021-03-23 | 2024-06-27 | null | 2024-09-30 | 2021-03-23 | 2021-03-25 | ACTUAL | 2024-09-30 | 2024-10-08 | ACTUAL | null | null | null | 2024-09-30 | 2024-10-08 | ACTUAL | 2021-12-01 | ACTUAL | 2021-12-01 | 2024-09 | 2024-09-30 | 2022-11-03 | ACTUAL | 2022-11-03 | 2022-08-04 | ACTUAL | 2022-08-04 | null | INTERVENTIONAL | null | null | Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy | Phase 2 Study of Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy | TERMINATED | null | PHASE2 | 13 | ACTUAL | Cartesian Therapeutics | null | 1 | null | Sponsor decision | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT04830462 | null | 2021-03-31 | null | null | 2023-05-15 | 2021-03-31 | 2021-04-05 | ACTUAL | null | null | null | null | null | null | 2023-05-15 | 2023-05-16 | ACTUAL | 2021-04-15 | ACTUAL | 2021-04-15 | 2023-05 | 2023-05-31 | 2023-05-01 | ACTUAL | 2023-05-01 | 2023-05-01 | ACTUAL | 2023-05-01 | null | INTERVENTIONAL | null | null | Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation | Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation | COMPLETED | null | PHASE4 | 32 | ACTUAL | Herlev and Gentofte Hospital | null | 2 | null | null | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | null | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | OTHER | null | null | null | null | null | null | 2,023 | 1 |
NCT04700787 | null | 2021-01-06 | null | null | 2022-06-09 | 2021-01-06 | 2021-01-08 | ACTUAL | null | null | null | null | null | null | 2022-06-09 | 2022-06-13 | ACTUAL | 2021-04-30 | ACTUAL | 2021-04-30 | 2022-06 | 2022-06-30 | 2022-04-04 | ACTUAL | 2022-04-04 | 2022-03-25 | ACTUAL | 2022-03-25 | null | INTERVENTIONAL | null | null | Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents | A Phase 1, Multi-Center, Open-Label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Sulopenem and Sulopenem Etzadroxil + Probenecid in Adolescent Patients With Bacterial Infection | WITHDRAWN | null | PHASE1 | 0 | ACTUAL | Iterum Therapeutics, International Limited | null | 1 | null | Enrollment challenges and change in development plan necessitating a change in study design | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT02729714 | null | 2016-01-26 | 2024-06-11 | null | 2024-07-25 | 2016-04-05 | 2016-04-06 | ESTIMATED | 2024-07-25 | 2024-08-20 | ACTUAL | null | null | null | 2024-07-25 | 2024-08-20 | ACTUAL | 2016-04 | ACTUAL | 2016-04-30 | 2024-07 | 2024-07-31 | 2022-04 | ACTUAL | 2022-04-30 | 2022-04 | ACTUAL | 2022-04-30 | null | INTERVENTIONAL | null | null | A Pilot Study of Suvorexant for Insomnia in Parkinson Disease | A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Suvorexant for Insomnia in Parkinson Disease | COMPLETED | null | PHASE4 | 21 | ACTUAL | Burdick, Daniel, M.D. | Designed as a pilot study, so recruitment goal was low and consequently the sample size is small, limiting interpretation of the significance of the differences between suvorexant and placebo. | 2 | null | null | f | null | null | null | f | null | null | null | null | null | null | null | null | null | null | null | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | INDIV | null | null | null | null | null | null | 2,022 | 1 |
NCT05900648 | null | 2023-05-31 | null | null | 2024-04-26 | 2023-05-31 | 2023-06-12 | ACTUAL | null | null | null | null | null | null | 2024-04-26 | 2024-04-29 | ACTUAL | 2023-05-17 | ACTUAL | 2023-05-17 | 2024-04 | 2024-04-30 | 2024-02-09 | ACTUAL | 2024-02-09 | 2024-02-09 | ACTUAL | 2024-02-09 | null | INTERVENTIONAL | null | null | Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME) | Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME) | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | M.D. Anderson Cancer Center | null | 1 | null | 0 participant accrual | null | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | OTHER | null | null | null | null | null | null | 2,024 | 0 |
NCT02464657 | null | 2015-06-03 | 2021-06-08 | null | 2021-09-09 | 2015-06-04 | 2015-06-08 | ESTIMATED | 2021-09-09 | 2021-10-07 | ACTUAL | null | null | null | 2021-09-09 | 2021-10-07 | ACTUAL | 2015-07 | ACTUAL | 2015-07-31 | 2021-09 | 2021-09-30 | 2020-05-07 | ACTUAL | 2020-05-07 | 2020-05-07 | ACTUAL | 2020-05-07 | null | INTERVENTIONAL | null | null | Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | Phase I/II Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | COMPLETED | null | PHASE1/PHASE2 | 44 | ACTUAL | M.D. Anderson Cancer Center | null | 3 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | OTHER | null | null | null | null | null | null | 2,020 | 1 |
NCT03498391 | null | 2018-03-12 | null | null | 2023-02-06 | 2018-04-06 | 2018-04-13 | ACTUAL | null | null | null | null | null | null | 2023-02-06 | 2023-02-08 | ACTUAL | 2018-07-30 | ACTUAL | 2018-07-30 | 2023-02 | 2023-02-28 | 2023-05 | ESTIMATED | 2023-05-31 | 2023-05 | ESTIMATED | 2023-05-31 | null | INTERVENTIONAL | MSI | null | A Study of Human Multi-Sensory Integration | A Study of Human Multi-Sensory Integration: A Neurophysiologic Correlate of Conscious Perception | SUSPENDED | null | PHASE2 | 40 | ESTIMATED | University of Pennsylvania | null | 2 | null | Due to the impact of COVID-19 | f | null | null | null | t | t | f | null | null | t | null | null | null | null | null | NO | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | OTHER | null | null | null | null | null | null | 2,023 | 0 |
NCT03996369 | null | 2019-06-21 | 2022-11-28 | null | 2022-11-28 | 2019-06-21 | 2019-06-24 | ACTUAL | 2022-11-28 | 2022-12-21 | ACTUAL | null | null | null | 2022-11-28 | 2022-12-21 | ACTUAL | 2020-09-15 | ACTUAL | 2020-09-15 | 2022-01 | 2022-01-31 | 2021-12-07 | ACTUAL | 2021-12-07 | 2021-12-07 | ACTUAL | 2021-12-07 | null | INTERVENTIONAL | ELEVATE UC 12 | Full Analysis Set: All randomized participants who received at least 1 dose of study intervention. | Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis | COMPLETED | null | PHASE3 | 354 | ACTUAL | Arena Pharmaceuticals | null | 2 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | INDUSTRY | null | null | null | null | null | null | 2,021 | 1 |
NCT04267276 | null | 2020-02-11 | 2021-12-17 | null | 2022-05-05 | 2020-02-11 | 2020-02-12 | ACTUAL | 2021-12-17 | 2022-02-23 | ACTUAL | null | null | null | 2022-05-05 | 2022-06-01 | ACTUAL | 2020-02-18 | ACTUAL | 2020-02-18 | 2022-05 | 2022-05-31 | 2020-04-02 | ACTUAL | 2020-04-02 | 2020-04-02 | ACTUAL | 2020-04-02 | null | INTERVENTIONAL | null | Treated set (TS): The treated set includes all participants who were entered and treated with one dose of trial drug. The treated set will be used for safety analyses. | A Study in Healthy Men to Test How BI 1265162 is Taken up and Processed by the Body | Investigation of Metabolism and Pharmacokinetics of BI 1265162 (C-14) After Intravenous Administration (Part 1) and Investigation of Metabolism and Pharmacokinetics of BI 1265162 (C-14) After Oral Administration (Part 2) in Healthy Male Subjects Following a Non-randomized, Open-label, Single-dose, Single Arm Per Trial Part Mass Balance Design | TERMINATED | null | PHASE1 | 7 | ACTUAL | Boehringer Ingelheim | The study was interrupted due to COVID-19 crisis on 02-Apr-2020, after completion of Part 1. Further, the sponsor decided to discontinue the development of BI 1265162. Enrolment in Part 2 (oral administration of BI 1265162 (C-14)) did not take place. Decision to terminate trial was taken on 17-Dec-2020. | 2 | null | Due to the COVID-19 pandemic, the recruitment of new subjects was temporarily halted in March 2020. The study was permanently discontinued in December 2020. | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT02700841 | null | 2016-03-02 | 2024-01-29 | null | 2024-03-08 | 2016-03-02 | 2016-03-07 | ESTIMATED | 2024-03-08 | 2024-03-12 | ACTUAL | null | null | null | 2024-03-08 | 2024-03-12 | ACTUAL | 2020-01-09 | ACTUAL | 2020-01-09 | 2024-03 | 2024-03-31 | 2022-12-21 | ACTUAL | 2022-12-21 | 2022-12-21 | ACTUAL | 2022-12-21 | null | INTERVENTIONAL | null | null | Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation | A Phase II Study of Enhancing Anti-Tetanus Vaccine Response After Autologous Stem Cell Transplantation | TERMINATED | null | PHASE2 | 8 | ACTUAL | University of Nebraska | null | 2 | null | Study terminated prematurely due to poor recruitment. | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT02594111 | null | 2015-10-30 | 2020-06-08 | null | 2023-01-25 | 2015-10-30 | 2015-11-01 | ESTIMATED | 2020-06-26 | 2020-07-10 | ACTUAL | null | null | null | 2023-01-25 | 2023-02-21 | ACTUAL | 2013-05-30 | ACTUAL | 2013-05-30 | 2023-01 | 2023-01-31 | 2021-12-31 | ACTUAL | 2021-12-31 | 2019-08-30 | ACTUAL | 2019-08-30 | null | INTERVENTIONAL | Colchicine-PCI | null | Colchicine in Percutaneous Coronary Intervention | Anti-inflammatory Therapy During Percutaneous Coronary Intervention | COMPLETED | null | PHASE4 | 714 | ACTUAL | VA Office of Research and Development | null | 2 | null | null | f | null | null | null | t | t | f | null | null | t | null | null | null | null | null | NO | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | FED | null | null | null | null | null | null | 2,021 | 1 |
NCT05512949 | null | 2022-08-20 | 2023-11-30 | null | 2024-10-03 | 2022-08-20 | 2022-08-23 | ACTUAL | 2024-01-08 | 2024-01-09 | ACTUAL | null | null | null | 2024-10-03 | 2024-10-08 | ACTUAL | 2022-09-09 | ACTUAL | 2022-09-09 | 2022-08-23 | 2022-08-23 | 2023-10-19 | ACTUAL | 2023-10-19 | 2022-12-01 | ACTUAL | 2022-12-01 | null | INTERVENTIONAL | null | null | Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine | A Phase 2 Randomized, Open-Label, Multisite Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Vaccine | COMPLETED | null | PHASE2 | 229 | ACTUAL | National Institute of Allergy and Infectious Diseases (NIAID) | null | 3 | null | null | f | null | null | null | null | t | f | null | null | f | null | null | null | null | null | null | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | NIH | null | null | null | null | null | null | 2,023 | 1 |
NCT03345797 | null | 2017-10-10 | null | null | 2023-10-24 | 2017-11-14 | 2017-11-17 | ACTUAL | null | null | null | null | null | null | 2023-10-24 | 2023-10-26 | ACTUAL | 2018-03-01 | ACTUAL | 2018-03-01 | 2023-10 | 2023-10-31 | 2022-04-11 | ACTUAL | 2022-04-11 | 2020-04-11 | ACTUAL | 2020-04-11 | null | INTERVENTIONAL | null | null | Evaluation of Testosterone Nasal Gel in Hypogonadal Boys | A Multicenter, Open Label, Variable Dose, Two Arm Pilot Paediatric Phase 1 PK Study to Evaluate Testosterone Nasal Gel (4.5% w/w) in Hypogonadal Boys | TERMINATED | null | PHASE1 | 8 | ACTUAL | Acerus Pharmaceuticals Corporation | null | 2 | null | Lack of patients and commercial reasons | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT04890353 | null | 2021-05-11 | null | null | 2023-10-24 | 2021-05-17 | 2021-05-18 | ACTUAL | null | null | null | null | null | null | 2023-10-24 | 2023-10-25 | ACTUAL | 2021-12-01 | ACTUAL | 2021-12-01 | 2021-05 | 2021-05-31 | 2023-02-28 | ACTUAL | 2023-02-28 | 2023-02-08 | ACTUAL | 2023-02-08 | null | INTERVENTIONAL | null | null | Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke | Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke | TERMINATED | null | PHASE1/PHASE2 | 2 | ACTUAL | Xuanwu Hospital, Beijing | null | 2 | null | The interim analysis of another associated study is not very effective | f | null | null | null | null | f | f | null | null | null | null | null | null | null | null | null | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | OTHER | null | null | null | null | null | null | 2,023 | 0 |
NCT03990974 | null | 2019-06-18 | null | null | 2020-03-23 | 2019-06-18 | 2019-06-19 | ACTUAL | null | null | null | null | null | null | 2020-03-23 | 2020-03-25 | ACTUAL | 2020-09 | ESTIMATED | 2020-09-30 | 2020-03 | 2020-03-31 | 2021-07 | ESTIMATED | 2021-07-31 | 2021-06 | ESTIMATED | 2021-06-30 | null | INTERVENTIONAL | HCC | null | Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC After Liver Resection | Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in Hepatocellular Carcinoma After Liver Resection: A Multi-center, Randomized, Open-labelled Trial. | SUSPENDED | null | PHASE3 | 458 | ESTIMATED | Sun Yat-sen University | null | 2 | null | There were difficulties in implementation | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT02819518 | null | 2016-06-28 | 2022-06-08 | null | 2023-11-06 | 2016-06-28 | 2016-06-30 | ESTIMATED | 2022-06-08 | 2022-07-05 | ACTUAL | null | null | null | 2023-11-06 | 2023-11-09 | ACTUAL | 2016-07-27 | ACTUAL | 2016-07-27 | 2023-11 | 2023-11-30 | 2023-10-30 | ACTUAL | 2023-10-30 | 2021-06-15 | ACTUAL | 2021-06-15 | null | INTERVENTIONAL | null | null | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) | A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355) | COMPLETED | null | PHASE3 | 882 | ACTUAL | Merck Sharp & Dohme LLC | null | 5 | null | null | f | null | null | null | t | null | null | null | null | null | null | null | null | null | null | YES | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | INDUSTRY | null | null | null | null | null | null | 2,023 | 1 |
NCT02756663 | null | 2016-04-12 | null | null | 2016-11-07 | 2016-04-26 | 2016-04-29 | ESTIMATED | null | null | null | null | null | null | 2016-11-07 | 2016-11-08 | ESTIMATED | 2016-12 | null | 2016-12-31 | 2016-11 | 2016-11-30 | 2021-02 | ESTIMATED | 2021-02-28 | 2021-02 | ESTIMATED | 2021-02-28 | null | INTERVENTIONAL | PANORAMA-5 | null | Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | A Randomized, Triple-arm, Controlled, Open-label, Multicenter Phase II Study Assessing Two Different Doses of Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | Novartis | null | 3 | null | null | f | null | null | null | t | null | null | null | null | null | null | null | null | null | null | null | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT05506930 | null | 2022-08-12 | null | null | 2024-10-03 | 2022-08-17 | 2022-08-18 | ACTUAL | null | null | null | null | null | null | 2024-10-03 | 2024-10-08 | ACTUAL | 2022-08-17 | ACTUAL | 2022-08-17 | 2024-10 | 2024-10-31 | 2024-05-10 | ACTUAL | 2024-05-10 | 2024-05-09 | ACTUAL | 2024-05-09 | null | INTERVENTIONAL | null | null | ITM vs QL for Pediatric Open Lower Abdominal Procedures | Intrathecal Morphine Versus Bilateral Quadratus Lumborum Blocks for Perioperative Analgesia in Pediatric Patients Undergoing Open Lower Abdominal Procedures: A Prospective Randomized Trial | TERMINATED | null | PHASE4 | 14 | ACTUAL | Medical University of South Carolina | null | 2 | null | The study was stopped early based on the anecdotal evidence from a surgeon who felt one group was experiencing more side effects than the other. Exposing pediatric patients who would be assigned to the inferior arm was difficult to justify ethically. | f | null | null | null | t | t | f | null | null | f | null | null | null | null | null | null | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | OTHER | null | null | null | null | null | null | 2,024 | 0 |
NCT04473950 | null | 2020-06-12 | null | null | 2022-10-06 | 2020-07-13 | 2020-07-16 | ACTUAL | null | null | null | null | null | null | 2022-10-06 | 2022-10-10 | ACTUAL | 2020-01-08 | ACTUAL | 2020-01-08 | 2022-10 | 2022-10-31 | 2022-10-06 | ACTUAL | 2022-10-06 | 2022-10-06 | ACTUAL | 2022-10-06 | null | INTERVENTIONAL | null | null | The Effect of Chronic Pain on Delay Discounting in Methadone Patients | The Effect of Chronic Pain on Delay Discounting in Methadone Patients | TERMINATED | null | PHASE1 | 29 | ACTUAL | University of California, San Francisco | null | 2 | null | The COVID-19 Pandemic prevented us from meeting target goals. | f | null | null | null | f | t | f | null | null | f | null | null | null | null | null | YES | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT02334722 | null | 2015-01-06 | 2021-10-05 | null | 2021-12-14 | 2015-01-06 | 2015-01-08 | ESTIMATED | 2021-12-14 | 2021-12-15 | ACTUAL | null | null | null | 2021-12-14 | 2021-12-15 | ACTUAL | 2015-08-05 | ACTUAL | 2015-08-05 | 2021-12 | 2021-12-31 | 2020-10-07 | ACTUAL | 2020-10-07 | 2020-10-07 | ACTUAL | 2020-10-07 | null | INTERVENTIONAL | null | Subjects were screened against eligibility criteria. Subjects with a history of seizures, depression or use of psychiatric medications, Beck-Depression Inventory score over 14, biopsy only or other factors were determined ineligible. Potential participants who may have been eligible also declined participation. | 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients | A Shortened Antiepileptic Drug (AED) Course in Surgical Brain Tumor Patients: A Randomized Trial | COMPLETED | null | PHASE4 | 81 | ACTUAL | University of Florida | null | 2 | null | null | f | null | null | null | t | t | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | OTHER | null | null | null | null | null | null | 2,020 | 1 |
NCT01891994 | null | 2013-06-28 | 2018-11-14 | null | 2023-04-03 | 2013-06-28 | 2013-07-03 | ESTIMATED | 2018-11-14 | 2018-12-04 | ACTUAL | null | null | null | 2023-04-03 | 2023-04-25 | ACTUAL | 2013-06-28 | null | 2013-06-28 | 2023-03 | 2023-03-31 | 2022-08-24 | ACTUAL | 2022-08-24 | 2017-10-16 | ACTUAL | 2017-10-16 | null | INTERVENTIONAL | null | null | Extended Dosing With Eltrombopag for Severe Aplastic Anemia | Extended Dosing With Eltrombopag in Refractory Severe Aplastic Anemia | COMPLETED | null | PHASE2 | 40 | ACTUAL | National Institutes of Health Clinical Center (CC) | null | 1 | null | null | f | null | null | null | null | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | NIH | null | null | null | null | null | null | 2,022 | 1 |
NCT03736785 | null | 2018-11-02 | 2021-02-12 | null | 2021-02-12 | 2018-11-08 | 2018-11-09 | ACTUAL | 2021-02-12 | 2021-03-08 | ACTUAL | null | null | null | 2021-02-12 | 2021-03-08 | ACTUAL | 2018-11-15 | ACTUAL | 2018-11-15 | 2020-03 | 2020-03-31 | 2020-02-18 | ACTUAL | 2020-02-18 | 2020-02-18 | ACTUAL | 2020-02-18 | null | INTERVENTIONAL | null | All randomized participants. | A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus | A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin | COMPLETED | null | PHASE2 | 399 | ACTUAL | Eli Lilly and Company | null | 3 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | YES | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,020 | 1 |
NCT04430985 | null | 2020-06-08 | null | null | 2021-10-19 | 2020-06-11 | 2020-06-16 | ACTUAL | null | null | null | null | null | null | 2021-10-19 | 2021-10-27 | ACTUAL | 2020-09-30 | ACTUAL | 2020-09-30 | 2021-10 | 2021-10-31 | 2021-09-06 | ACTUAL | 2021-09-06 | 2021-09-06 | ACTUAL | 2021-09-06 | null | INTERVENTIONAL | IMMUNOX | null | FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer | FOLFOX + Immunotherapy With Intrahepatic Administration of Oxaliplatin for Patients With Multiple Non-resectable Liver Metastasis From Colorectal Cancer | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | Herlev Hospital | null | 1 | null | Problems identifying eligble patients | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT04011033 | null | 2019-07-03 | 2021-12-23 | null | 2024-09-28 | 2019-07-05 | 2019-07-08 | ACTUAL | 2024-09-28 | 2024-10-08 | ACTUAL | null | null | null | 2024-09-28 | 2024-10-08 | ACTUAL | 2018-03-01 | ACTUAL | 2018-03-01 | 2024-09 | 2024-09-30 | 2023-10-01 | ACTUAL | 2023-10-01 | 2020-03-01 | ACTUAL | 2020-03-01 | null | INTERVENTIONAL | null | null | Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC | Study of Adoptive Transfer of Invariant Natural Killer T Cells Combined With TAE/TACE to Treat Unresectable Hepatocellular Carcinoma (HCC): Phase II Clinical Trial | COMPLETED | null | PHASE2 | 60 | ACTUAL | Beijing YouAn Hospital | One limitation of our study is that patients only received two cycles of TAE and the duration of iNKT therapy was only 3 months; thus, our study was not long enough to adequately assess OS. A second limitation was the small sample size, but our promising data prompts future studies in larger cohorts to more thoroughly delineate how iNKT cell therapy can be used in the context of TACE/TAE to improve therapeutic options for patients with unresectable HCC. | 2 | null | null | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | OTHER | null | null | null | null | null | null | 2,023 | 1 |
NCT05133180 | null | 2021-11-15 | 2024-03-07 | null | 2024-05-10 | 2021-11-15 | 2021-11-24 | ACTUAL | 2024-05-10 | 2024-06-07 | ACTUAL | null | null | null | 2024-05-10 | 2024-06-07 | ACTUAL | 2022-01-19 | ACTUAL | 2022-01-19 | 2024-05 | 2024-05-31 | 2022-12-19 | ACTUAL | 2022-12-19 | 2022-09-22 | ACTUAL | 2022-09-22 | null | INTERVENTIONAL | null | The Full Analysis Set (FAS) population included all patients who were randomized and received at least one dose of the investigational product. | Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study) | A 4-week, Phase III, Multicenter, Double-masked, Vehicle-controlled Clinical Study to Evaluate Safety and Efficacy of Oxervate® (Cenegermin) 20 mcg/mL Ophthalmic Solution vs Vehicle in Severe Sjogren's Dry Eye Disease | COMPLETED | null | PHASE3 | 104 | ACTUAL | Dompé Farmaceutici S.p.A | null | 2 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | INDUSTRY | null | null | null | null | null | null | 2,022 | 1 |
End of preview. Expand
in Data Studio
Dataset for "Automatically Labeling Clinical Trial Outcomes: A Large-Scale Benchmark for Drug Development"
Website: https://chufangao.github.io/CTOD/
Paper: https://arxiv.org/abs/2406.10292
Code: https://github.com/chufangao/ctod
Descriptions:
- human_labels contains the manually annotated subset. We follow the same rule-based termination of incomplete status and p-value < 0.05 as in the automated labeling step to remove the easy cases. The additional metadata is taken from studies.txt from CTTI.
- linkage contains the weakly linked trials as predicted based on text similarity. E.g. if a similar trial is found in phase 3 from a trial in phase 2, then they are considered "linked". We use a reranking method after the initial text similarity retrieval to further refine relevance. "connected next phase" implies similar text similarity AND positive reranking. "weakly connected next phase" implies similar text similarity BUT negative reranking.
- news contains the top 10 most similar (cosine text similarity) headlines to the trial, 0 being the most similar. "valid_sentiments" is a list of sentiments from a binary sentiment classifier, and "mode" is the most popular sentiment.
- phase1_CTO_preds, phase2_CTO_preds, phase3_CTO_preds contain phase-specific CTO predictions. Note that each phase may have different columns due to the phase-specific thresholding of weak supervision sources. Some columns are duplicated (e.g. gpt1, gpt2) for dynamic programming purposes. Duplicated columns may be ignored in practice. The most relevant columns are ["nct_id", "pred", "pred_proba"], where "pred_proba" is the predicted probability of trial success.
- pubmed_gpt contains linked GPT predictions on related trial publications
- stocks_and_amendents contains scraped stock price Slope from a 5-day moving average. The Slope is calculated from: (trial completion date, trial completion date + 7 days). This file also contains the scraped number of amendments made to the trial on clinicaltrials.gov.
CTTI.zip is from: Aggregate Analysis of ClinicalTrials.gov (AACT) Database. Clinical Trials Transformation Initiative (CTTI). Available at: https://aact.ctti-clinicaltrials.org/ (Accessed: 10/2024).
- Downloads last month
- 735